In-House CAR-T: una revisión

CAR-T therapy poses multiple barriers, such as high cost and limited availability of commercially patented products. In different hospital and academic centers, the production of CAR-T “in house” has been developed as an alternative to overcome these obstacles. The objective of this narrative review is to describe the information reported regarding the manufacturing, effectiveness and safety of “in house” or “academic” CAR-T products; Through a non-systematic search of the literature in the NCBI-PUBMED databases, series and case reports were included, as well as Phase I and II studies available in English and Spanish. In this review, reports from Spain, India, Canada, China, Israel, and Brazil have been identified, showing the feasibility of CAR-T production in academic centers with a low frequency of production failures, with favorable clinical results, predictable toxicity profile, and potential significant resource savings. In particular, the development of academic CAR-Ts such as ARI-0001 and its approval for hospital use in Spain opens a great opportunity to improve access to CAR-T therapy in Europe, and potentially in lower-resource countries such as Latin America.